Phase 4 N=28 Randomized Double-blind Treatment

Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects

Endothelial Dysfunction

Bottom Line

View on ClinicalTrials.gov: NCT00376246 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2020

Primary outcome: Primary: Percent Change in Flow Mediated Dilation — 12.3; 11.6; 10.9; 11.1 percent change

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Ezetimibe (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of California, San Diego
Primary completion: Apr 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Percent Change in Flow Mediated Dilation	12.3; 11.6; 10.9; 11.1; 12.8; 13.9	—
SECONDARY Lipid Profile- Change in LDL(Low Density Lipoprotein)	92; 102; 89; 104; 87; 101	—

Summary

The objective of this study is to show that Ezetimibe will improve endothelial function following high cholesterol meals in healthy subjects by decreasing absorption of cholesterol and thus affecting concentration and composition of remnant-like particles.

Eligibility Criteria

Inclusion Criteria

healthy adults over 18 yrs of age

Exclusion Criteria

presence of known metabolic syndrome
as history of coronary artery disease
hypertension
diabetes
cardiomyopathy
tobacco use

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00376246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.